A5038126736- Prostate Cancer Treatment and Research
- HIV/AIDS Research and Interventions
- Prostate Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- HIV Research and Treatment
- Adolescent Sexual and Reproductive Health
- HIV-related health complications and treatments
- Bladder and Urothelial Cancer Treatments
- Radiopharmaceutical Chemistry and Applications
- HIV/AIDS drug development and treatment
- Pain Management and Opioid Use
- Cancer Risks and Factors
- Cancer, Lipids, and Metabolism
- Aortic aneurysm repair treatments
- Oral microbiology and periodontitis research
- Chronic Myeloid Leukemia Treatments
- Cerebrovascular and Carotid Artery Diseases
- Colorectal Cancer Treatments and Studies
- Oral and gingival health research
- Adolescent and Pediatric Healthcare
- Anatomy and Medical Technology
- Advanced Breast Cancer Therapies
- Intracranial Aneurysms: Treatment and Complications
- Cancer, Hypoxia, and Metabolism
- Hemodynamic Monitoring and Therapy
Bristol-Myers Squibb (United States)
2023
Philips (United States)
2019
Philips (Finland)
2019
Cancer Research And Biostatistics
2015
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2004-2014
University of Colorado Denver
2009
University of Colorado Cancer Center
2009
Dana-Farber Cancer Institute
2008-2009
University of Chicago
2009
Duke University
2008-2009
3509 Background: PF-02341066 (PF) is a selective, ATP-competitive, small molecule oral inhibitor of the c-Met/HGFR and ALK receptor tyrosine kinases that has not previously been tested in humans. A Phase 1 dose-escalation trial evaluating PF as an single agent was conducted to investigate safety, PK PD patients (pts) with advanced cancer (excluding leukemias). Methods: administered under fasting conditions QD or BID on continuous schedule pts successive dose-escalating cohorts at doses...
Purpose Pain from castration-refractory prostate cancer (CRPC) bone metastases is a common event. Although it assumed that pain represents an adverse prognostic factor, this variable has not been extensively evaluated. The objective of study was to determine whether men with CRPC who had higher interference scores at baseline worse clinical outcomes compared lower scores. Patients and Methods Data three randomized phase III multicenter trials conducted by the Cancer Leukemia Group B 1992...
To explore whether progression-free survival (PFS) or biochemical PFS can be used as a predictor of overall (OS) and to investigate the dependence between OS in men with castrate-resistant prostate cancer.Data from nine Cancer Leukemia Group B trials that enrolled 1,296 1991 2004 were pooled. Men eligible if they had cancer progressed during androgen deprivation therapy did not receive prior treatment chemotherapy, immunotherapy, other nonhormonal therapy. Landmark analyses at 3 6 months...
Abstract BACKGROUND. Obesity has a variety of adverse health outcomes, but to the authors' knowledge, effect obesity on outcome in patients with advanced prostate cancer is not known. For this reason, correlation between an elevated body mass index (BMI) and clinical outcomes metastatic, castration–recurrent (CRPC) was evaluated. METHODS. A total 1226 men CRPC who were enrolled 9 prospective trials conducted by Cancer Leukemia Group B (CALGB) for treatment metastatic disease considered....
<h3>BACKGROUND AND PURPOSE:</h3> Some retrospective studies have found that the aneurysm wall enhancement on high-resolution MR vessel postgadolinium T1WI has potential to distinguish unstable aneurysms. This study aimed identify hemodynamic characteristics differ between enhanced and nonenhanced areas of T1WI. <h3>MATERIALS METHODS:</h3> TOF-MRA 25 patients were fused localize area wall. Using computational fluid dynamics, we studied models. Mean static pressure, mean shear stress,...
After randomized trials in the 1980s, doxorubicin (DOX) was added to dactinomycin plus vincristine as standard chemotherapy for patients who had Stage III Wilms tumor (WT) of favorable histology (FH). Double-agent retained with II disease. In this study, authors reevaluated efficacy DOX using extended follow-up and additional patients.The relative risks (RR) (DOX vs. no DOX) disease recurrence mortality were estimated II-III/FH WT enrolled third fourth National Tumor Studies (NWTS-3 NWTS-4)....
Three-dimensional ultrasound (3D-US) examination is a relatively new modality that can be used for abdominal aortic aneurysm (AAA) surveillance, and may offer improved reproducibility over conventional two-dimensional (2D-US) examination. The aim of this study was to evaluate the interoperator maximum anterior-to-posterior diameter by nonphysician technicians in typical vascular laboratory setting, on patients with infrarenal AAAs using 3D-US 2D-US examination.A total 134 consecutive...
We pilot tested a Motivational Interviewing (MI) -based counseling intervention for individuals with Acute HIV Infection (AHI) to reduce risky sexual behavior in Lilongwe, Malawi.Twenty-eight diagnosed AHI were randomized receive either brief education alone, or the plus MI-based intervention, called Uphungu Wanga. Participants Wanga received four sessions delivered on day of diagnosis, three days later and at weeks 1 2 booster session week 8; participants followed 24 from diagnosis. An...
No AccessJournal of UrologyAdult urology1 Jul 2006Clinical Outcomes by Age in Men With Hormone Refractory Prostate Cancer: A Pooled Analysis 8 Cancer and Leukemia Group B (CALGB) Studies Susan Halabi, Nicholas J. Vogelzang, San-San Ou, Wm. Kevin Kelly, Eric Small HalabiSusan Halabi Department Biostatistics Bioinformatics, Durham, North Carolina Statistical Center, , VogelzangNicholas Vogelzang Nevada Institute University School Medicine, Las Vegas, OuSan-San Ou KellyWm. Kelly Yale New Haven,...
A prior report suggested that radical prostatectomy may confer a survival advantage to patients with metastatic castration recurrent prostate cancer. Therefore, pooled analysis of 9 trials performed by Cancer and Leukemia Group B was done determine if men cancer who underwent had improved clinical outcomes, such as overall, specific, progression-free PSA survival, than did not undergo prostatectomy.Data from multi-institutional were combined. Eligible progressive during androgen deprivation...
Abstract BACKGROUND. A multicenter phase 2 trial was conducted to evaluate the safety and feasibility of radiotherapy after paclitaxel, estramustine phosphate, carboplatin (TEC) plus androgen deprivation therapy in previously untreated unfavorable‐risk localized prostate cancer patients. METHODS. Patients with high‐risk were treated 4 cycles (16 weeks) continuous weekly paclitaxel at 80 mg/m intravenously 280 mg orally 3 times a day for 5 days week (area under curve 6) on Day 1 every cycle...
5113 Background: In this proposed study, we developed and validated a novel composite clinical benefit endpoint constructed from symptoms that have intrinsic importance in 800 men with CRPC who were treated front-line chemotherapy. Methods: Data nine multimember trials (five phase II four randomized III studies) conducted by the Cancer Leukemia Group B (CALGB) 1992–2004 combined. Eligible patients had progressive adenocarcinoma of prostate during androgen ablation (despite castrate...
4649 Background: D/E is a known active regimen in HRPC with an associated prolongation of survival. Exisulind induces apoptosis and double blind trial men failing prostatectomy (RP) suppressed the increase prostate specific antigen (PSA). Methods: Eighty chemotherapy-naïve were enrolled multi-institutional from December 2002 to January 2004. Treatment consisted E-280 mg po TID for days 1–5, D 70 mg/m2 on day 2, exisulind 250 BID daily. Dexamethasone 8 1–3, warfarin 2 The primary endpoints...
4622 Background: To determine if men 65 years of age and older have worse clinical outcomes than younger with hormone refractory prostate cancer (HRPC). Methods: Data from eight multicenter trials (four phase II four randomized III studies) conducted by the Cancer Leukemia Group B (CALGB) 1992–2003 were combined. Eligible patients had progressive adenocarcinoma after androgen ablation (with castrate testosterone levels), an ECOG performance status 0–2, adequate hematologic, renal hepatic...
Polymerase chain reaction (PCR) based tests are commonly used to diagnose various infections. Such assumed be highly 'sensitive', however, no consensus definition of, or method for estimating, sensitivity exists. Hughes and Totten proposed that defined as a function of the number target DNA molecules in sample with specificity corresponding case where there is molecule present. They then developed parametric, non-parametric semi-parametric models estimating curve. In this paper general model...
4556 Background: Previous articles have reported that an elevated BMI was associated with increased risk of biochemical failure in hormone sensitive patients. We asked the question as to whether predicts for worst clinical outcomes, namely overall survival (OS) and prostate-cancer (PCS), among 1,216 men HRPC. Methods: Patients were enrolled on eight trials conducted by Cancer Leukemia Group B (CALGB). Eligible patients had progressive prostate cancer during androgen deprivation therapy (with...